Skip Navigation Links   >   Home   >   News & Media
28 July 2020

OCT Appoints Dr Valentino Parravicini as Chief Scientific Officer

OCT Appoints Dr Valentino Parravicini as Chief Scientific Officer as the business prepares for exciting new developments

Oxford Cannabinoid Technologies (“OCT”), a UK-based biotechnology firm researching the potential of cannabinoids for treating a range of acute and chronic conditions, today announces the appointment of Dr Valentino Parravicini PhD as its new Chief Scientific Officer (“CSO”).  Dr Parravicini has joined the business to support the delivery of its objective to become a global leader in developing cannabinoid-based prescription medicine for indications in oncology, pain, immunology and neurology.

Dr Parravicini will oversee all of OCT’s ongoing drug discovery and development studies, including pre-clinical development of OCT461201, the company’s lead, highly selective and potent CB2 agonist, believed to be a potentially effective treatment for Irritable Bowel Syndrome (“IBS”) and other diseases. He will work closely with OCT’s lead business and research partners, while developing new research partnerships with other leading academic and commercial institutions around the world.

Dr Parravicini has a long and distinguished career in the fields of oncology, inflammation and immunology. He has led ground-breaking in vitro and in vivo projects and undertaken award-winning work in pharma and biotech focussed on small molecule and cell therapy approaches to autoimmunity and haematological malignancies. He is also an extensively published author on his discoveries and innovations with high-impact peer-reviewed publications in the fields of immunology and molecular virology.

Valentino Parravicini said: “I am delighted to be joining the team at Oxford Cannabinoid Technologies whose reputation precedes them. OCT’s search for transformative therapies to meet currently unmet medical needs is a perfect match with my past professional experience and my unquenchable desire to see how we can best harness cannabinoids to transform the lives of millions of people so that they live longer, more active lives.”

John Lucas, Chief Commercial Officer of OCT, said: “We are thrilled to have Valentino come on board. He has exactly the right kinds of skills sets that we need to help take OCT on the next stage of its exciting journey. This is a time of extraordinary and dynamic change and innovation in our sector and we are delighted to have him at our side to help us be that change and make it come alive for millions of sufferers around the world.”

    All News

    • OCT Appoints Dr Valentino Parravicini as Chief Scientific Officer as the business prepares for exciting new developments

      OCT Appoints Dr Valentino Parravicini as Chief Scientific Officer

      28 July 2020 OCT Press Release
    • Cannabinoids in medicine part 5: Treating COVID-19

      17 June 2020 Open Access Government
    • Why the Government should continue to invest in Life Sciences post COVID-19

      Why the government should continue to invest in Life Sciences post COVID-19

      01 June 2020 OCT blog - John Lucas, COO
    • OCT researchers publish new study examining genes involved in treating neuropathic pain

      19 April 2020 OCT Press Release
    • OCT announces pre-clinical development of new cannabinoid compound ‘OCT461201’ to treat IBS

      03 April 2020 OCT Press Release
    • Cannabinoids in medicine part 4: Epilepsy

      30 March 2020 Open Access Government
    • Cannabinoids in Medicine Part 3: Psoriasis and Rheumatoid Arthritis

      07 January 2020 Open Access Government
    • Cannabinoids in medicine Part 2: Pain

      11 October 2019 Open Access Government
    • Cannabinoids in medicine Part 1: Cancer

      22 August 2019 Open Access Government
    • An interview with Neil Mahapatra

      08 January 2019 The Times Magazine
    • High life: the start-up hoping to unlock the secrets of medical cannabis

      09 August 2018 Evening Standard
    • Oxford Cannabinoid Technologoies goes global as it announces close of series a fundraising round and management team line-up

      28 June 2018 OCT Press Release
    • Embracing the medical potential of cannabinoids

      01 June 2017 The Medicine Maker
    • Smashing the stigma with science

      01 June 2017 The Medicine Maker
    • Oxford University launches £10m research project into medical marijuana

      16 March 2017 Evening Standard
    • Oxford University to launch study on medical benefits of marijuana

      16 March 2017 The Telegraph
    • Oxford University to launch multimillion-dollar medical marijuana research program

      16 March 2017 CNBC
    • Oxford University launches £10m marijuana research programme

      16 March 2017 BBC
    • The University of Oxford and Kingsley Capital Partners announce ground breaking Cannabinoid Biomedicine Research Programme

      15 March 2017 OCT Press Release